Zacks
Does Benitec Biopharma (BNTC) Have the Potential to Rally 83.87% as Wall Street Analysts Expect?
📈
AI Sentiment
Highly Positive
8/10
- Home
- BNTC
as of 12-26-2025 4:00pm EST
$13.10
+$0.05
+0.38%
Benitec Biopharma Inc is a clinical-stage biotechnology company focused on the advancement of novel genetic medicines. Its technology has the potential to provide a one-shot cure for a wide range of diseases that are addressed by strict ongoing treatment regimens or that have no effective treatment or only palliative care options. The Company is developing a silence and replace-based therapeutic (BB-301) for the treatment of Oculopharyngeal Muscular Dystrophy (OPMD), a chronic, life threatening genetic disorder.
| Founded: | 1995 | Country: | United States |
| Employees: | N/A | City: | HAYWARD |
| Market Cap: | 405.7M | IPO Year: | N/A |
| Target Price: | $28.25 | AVG Volume (30 days): | 253.4K |
| Analyst Decision: | Strong Buy | Number of Analysts: | 4 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -1.06 | EPS Growth: | N/A |
| 52 Week Low/High: | $9.70 - $17.15 | Next Earning Date: | 02-13-2026 |
| Revenue: | N/A | Revenue Growth: | N/A |
| Revenue Growth (this year): | N/A | Revenue Growth (next year): | N/A |
AI-Powered BNTC Daily Prediction
Machine learning model trained on 25+ technical indicators
Updated a day ago
AI Recommendation
hold
Model Accuracy: 66.89%
66.89%
Confidence
Disclaimer: This prediction is generated by an AI model and should not be considered as financial advice. Always conduct your own research and consult with financial professionals before making investment decisions.
Stock Insider Trading Activity of Benitec Biopharma Inc. (BNTC)
SUVRETTA CAPITAL MANAGEMENT, LLC
Buy
Director, 10% Owner
BNTC Dec 22, 2025
Avg Cost/Share
$12.08
Shares
19,542
Total Value
$236,067.36
Owned After
9,577,475
SUVRETTA CAPITAL MANAGEMENT, LLC
Buy
Director, 10% Owner
BNTC Dec 19, 2025
Avg Cost/Share
$11.48
Shares
16,384
Total Value
$188,088.32
Owned After
9,577,475
SUVRETTA CAPITAL MANAGEMENT, LLC
Buy
Director, 10% Owner
BNTC Dec 18, 2025
Avg Cost/Share
$11.24
Shares
10,215
Total Value
$114,816.60
Owned After
9,577,475
SUVRETTA CAPITAL MANAGEMENT, LLC
Buy
Director, 10% Owner
BNTC Nov 7, 2025
Avg Cost/Share
$13.50
Shares
1,481,481
Total Value
$19,999,993.50
Owned After
9,577,475
| Insider | Ticker | Relationship | Date | Transaction | Avg Cost | Shares | Total Value | Owned After | SEC Forms |
|---|---|---|---|---|---|---|---|---|---|
| SUVRETTA CAPITAL MANAGEMENT, LLC | BNTC | Director, 10% Owner | Dec 22, 2025 | Buy | $12.08 | 19,542 | $236,067.36 | 9,577,475 | |
| SUVRETTA CAPITAL MANAGEMENT, LLC | BNTC | Director, 10% Owner | Dec 19, 2025 | Buy | $11.48 | 16,384 | $188,088.32 | 9,577,475 | |
| SUVRETTA CAPITAL MANAGEMENT, LLC | BNTC | Director, 10% Owner | Dec 18, 2025 | Buy | $11.24 | 10,215 | $114,816.60 | 9,577,475 | |
| SUVRETTA CAPITAL MANAGEMENT, LLC | BNTC | Director, 10% Owner | Nov 7, 2025 | Buy | $13.50 | 1,481,481 | $19,999,993.50 | 9,577,475 |
Latest Benitec Biopharma Inc. News
BNTC Breaking Stock News: Dive into BNTC Ticker-Specific Updates for Smart Investing
Compare BNTC vs Leading Stocks
See how BNTC stacks up against similar companies in the market
Head-to-Head Comparisons
Share on Social Networks:
Tools & Resources
Enhance your trading experience with our free tools
Disclaimer
The information presented on this page, "BNTC Benitec Biopharma Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.